Jazz Pharmaceuticals (JAZZ) PT Lowered to $190 at B.Riley/FBR
B.Riley/FBR analyst David Buck lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $190.00 (from $219.00) while maintaining a Buy rating.
B.Riley/FBR analyst David Buck lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $190.00 (from $219.00) while maintaining a Buy rating.